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Informal Formalities
To Patent or Not To Patent,  That is The Question: 
Embryonic Stem Cell Patents Rejected in Europe
by Amer Raja
Recently, the European Court of Justice was 
asked to determine the patentability of stem-cell 
products derived from human embryos.  While the 
question submitted to the Advocate General was not 
as straightforward, both the Advocate General and the 
Court seemed to have little trouble in taking a position 
in this case.  At the heart of this query was “whether 
the human embryonic stem cells which serve as base 
material for the patented processes constitute ‘embryos’ 
within the meaning 
of Article 6(2)(c) of 
the Directive.”  The 
Court’s decision in 







of products arising 
from base material.
The dispute 
arose from Mr. 
Oliver Brüstle’s 
patent on “isolated 




stem cells used to 
treat neurological 
diseases.”  Mr. 
Brüstle works at 
the University of 
Bonn in Germany as a Professor of Reconstructive 
Neurobiology.  Greenpeace, along with a number 
of religious organizations, contested the patent and 
sued for “ethical reasons,” to invalidate Mr. Brüstle’s 
ownership rights in the patent.  The patent was 
declared “invalid insofar as it covers precursor cells 
obtained from human embryonic stem cells,” by the 
Federal Patent Court (Bundespatentgericht), and the 
case was subsequently referred to the European Court 
of Justice.
The issues that the European Court of Justice was 
asked to determine largely arose from the European 
Union’s approach to patentability and embryonic 
research.  The relevant legislation and treaty language 
can be found in the German national law, TRIPS 
article 27, CGEP articles 52(1) and 53, and Directive 
98/44 with respect to article 6(2)(c).  Of these sources 
of law, the Court particularly focused on the directive 
since the case turned on the definition of “embryo” and 
the “dignity 
and integrity” 










in the laws 






a stem cell 
or purified 
precursor 
cell could be 
considered 
to be an 
embryo, 
the Court first attempted to define and interpret the 
concept of human embryo with respect to article 6(2)
(c).
To give some context to the Court’s ruling, I 
will briefly outline a few relevant points in stem cell 
research.  While there are a few different types of stem 
cells, embryonic stem cells are probably the most 
potent and controversial since production starts with 
the fertilization of a human ovum (“egg”).  Within a 
few days after fertilization, a blastocyst is formed, which 
The following blog post was published on www.ipbrief.net on October 29, 2011.
is comprised of a number of cells and regarded by a 
number of scientists to be an early stage embryo.  In 
the interim period between fertilization and blastocyst 
formation, the ovum (now a “zygote”) undergoes a 
number of changes.
These changes include the formation of totipotent 
cells (unspecialized cells which can form anything 
in a human body) and eventually pluripotent cells 
(which can form a number of things but within one of 
three categories).  Totipotent cells precede pluripotent 
cells chronologically and denote different stages of 
development.  Therefore, the issue the Court had to 
wrestle with determining the moment at which an 
embryo could be regarded to exist, since it would be 
protected by national law.
In the end, the Court determined that while the 
pluripotent cells and blastocyst are more specialized in 
the development of a human being, that totipotent cells 
were also necessarily included in the definition of an 
embryo.  The Court stated that “[A]ny human ovum 
must, as soon as fertilised, be regarded as a ‘human 
embryo’ within the meaning and for the purposes of 
the application of Article 6(2)(c) of the Directive, since 
that fertilisation is such as to commence the process of 
development of a human being.”  This definition is also 
meant to include traditionally and non-traditionally 
matured ova, such as in parthenogenesis (maturation 
of an ovum without fertilization).  However, the Court 
seems to have left open the question of whether a stem 
cell obtained at the blastocyst stage is an embryo, which 
may lead to further debate in the field.  In addition 
to its determination that an embryo exists once an 
ovum is fertilized, the Court determined that scientific 
research and industrial use of embryos cannot lead to 
patents and further excluded any materials obtained 
from the destruction or use of embryos as base material.
While the implications of this decision are not 
entirely clear at this point, Mr. Brüstle and a number 
of other scientists have articulated that this decision 
comes as a huge blow to the scientific community.  
The scientists feel that this decision will serve as a 
huge setback in the development of stem cell products 
and may result in a greater advantage for their Asian 
counterparts.  Greenpeace, the Catholic Church, and 
a number of religious organizations, however, feel that 
this decision comes as “a victory for human dignity.”
However, Mr. Julian Hitchcock, a lawyer with Field 
Fisher Waterhouse LLP also voiced his opinion that 
this decision may not actually be too detrimental to 
stem cell research; it could very well provide scientists 
and researchers with more freedom to not “worry about 
infringing someone else’s patent.”  Furthermore, he 
points out that “While the ruling restricts patentability 
of such inventions, it doesn’t in any way restrict the use 
of embryonic stem cells.”
As a result the Court’s decision may not really 
do much at all in the way of discouraging stem cell 
research – it may very well promote it.  While in the 
United States we have the Bayh-Dole act to promote 
non-commercial research which can later become 
commercialized; embryonic stem cell products could 
very well start as non-commercial ventures in Europe 
and later lead to greater developments that may be 
nevertheless be patentable as well.  The incentive in 
obtaining a patent and conducting a research may 
merely be delayed as opposed to entirely eliminated.
Furthermore, some practitioners have even posited 
the idea that researchers could depend on trade secrets 
and regulatory procedures to sidestep the hurdle.  
Lastly, the Court through its ruling has not foreclosed 
all embryonic stem cell research as such.  Scientists may 
still be able to patent embryonic stem cell products by 
establishing that a stem cell obtained at the blastocyst 
should not be considered an embryo and therefore 
could potentially be patentable subject matter.  In sum, 
the Court’s decision may provide very little guidance 
at all, and certainly leaves open the question of how 
to implement this new restriction on patentability; 
it will certainly be interesting to see how scientists, 
organizations, and Courts deal with this matter in the 
coming months and years.
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